ono pharm - OPHLY

OPHLY

Close Chg Chg %
4.77 -0.07 -1.47%

Closed Market

4.70

-0.07 (1.47%)

Volume: 17.85K

Last Updated:

Jan 13, 2026, 3:58 PM EDT

Company Overview: ono pharm - OPHLY

OPHLY Key Data

Open

$4.71

Day Range

4.70 - 4.72

52 Week Range

3.21 - 4.82

Market Cap

$6.77B

Shares Outstanding

1.41B

Public Float

N/A

Beta

0.25

Rev. Per Employee

N/A

P/E Ratio

20.52

EPS

$0.23

Yield

300.44%

Dividend

$0.09

EX-DIVIDEND DATE

Sep 30, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

28.35K

 

OPHLY Performance

1 Week
 
-1.26%
 
1 Month
 
2.40%
 
3 Months
 
18.90%
 
1 Year
 
37.43%
 
5 Years
 
-51.79%
 

OPHLY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About ono pharm - OPHLY

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

OPHLY At a Glance

Ono Pharmaceutical Co., Ltd.
1-8-2 Kyutaromachi
Osaka, Osaka 541-8564
Phone 81-6-6263-5670 Revenue 3.19B
Industry Pharmaceuticals: Major Net Income 328.28M
Sector Health Technology Employees 4,287
Fiscal Year-end 03 / 2026
View SEC Filings

OPHLY Valuation

P/E Current 20.522
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 15.33
Price to Sales Ratio 1.576
Price to Book Ratio 0.962
Price to Cash Flow Ratio 9.31
Enterprise Value to EBITDA 7.847
Enterprise Value to Sales 1.455
Total Debt to Enterprise Value 0.211

OPHLY Efficiency

Revenue/Employee 744,958.277
Income Per Employee 76,576.602
Receivables Turnover 3.436
Total Asset Turnover 0.486

OPHLY Liquidity

Current Ratio 3.069
Quick Ratio 2.564
Cash Ratio 1.419

OPHLY Profitability

Gross Margin 68.903
Operating Margin 13.019
Pretax Margin 12.16
Net Margin 10.279
Return on Assets 4.992
Return on Equity 6.27
Return on Total Capital 5.284
Return on Invested Capital 5.824

OPHLY Capital Structure

Total Debt to Total Equity 18.746
Total Debt to Total Capital 15.787
Total Debt to Total Assets 13.785
Long-Term Debt to Equity 14.506
Long-Term Debt to Total Capital 12.216
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ono Pharm - OPHLY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
3.22B 3.30B 3.48B 3.19B
Sales Growth
+10.27% +2.62% +5.35% -8.13%
Cost of Goods Sold (COGS) incl D&A
858.30M 833.14M 899.07M 993.12M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
157.70M 128.77M 125.45M 176.41M
Depreciation
88.15M 72.20M 69.67M 69.31M
Amortization of Intangibles
69.55M 56.58M 55.77M 107.10M
COGS Growth
+3.22% -2.93% +7.91% +10.46%
Gross Income
2.36B 2.47B 2.58B 2.20B
Gross Income Growth
+13.08% +4.63% +4.48% -14.62%
Gross Profit Margin
+73.31% +74.75% +74.14% +68.90%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.33B 1.34B 1.45B 1.78B
Research & Development
675.24M 703.56M 775.74M 983.05M
Other SG&A
659.58M 639.35M 673.50M 801.70M
SGA Growth
+9.74% +0.61% +7.92% +23.15%
Other Operating Expense
- - - (3.17M)
-
Unusual Expense
67.57M 58.04M 947.43K 10.79M
EBIT after Unusual Expense
955.05M 1.07B 1.13B 404.98M
Non Operating Income/Expense
(19.71M) (5.70M) 2.85M (5.90M)
Non-Operating Interest Income
293.67K 516.54K 7.74M 10.38M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
658.52K 937.15K 726.13K 10.72M
Interest Expense Growth
-12.70% +42.31% -22.52% +1,376.98%
Gross Interest Expense
658.52K 937.15K 726.13K 10.72M
Interest Capitalized
- - - -
-
Pretax Income
934.67M 1.06B 1.13B 388.34M
Pretax Income Growth
-1.74% +13.31% +6.91% -65.70%
Pretax Margin
+29.07% +32.10% +32.57% +12.16%
Income Tax
216.60M 225.94M 246.84M 60.10M
Income Tax - Current - Domestic
89.15M 302.69M 279.71M 138.25M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
127.46M (76.75M) (32.87M) (78.16M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
718.00M 833.20M 885.46M 329.06M
Minority Interest Expense
1.48M 1.40M 428.76K 780.58K
Net Income
716.53M 831.80M 885.03M 328.28M
Net Income Growth
+0.75% +16.09% +6.40% -62.91%
Net Margin Growth
+22.28% +25.21% +25.46% +10.28%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
716.53M 831.80M 885.03M 328.28M
Preferred Dividends
- - - -
-
Net Income Available to Common
716.54M 831.80M 885.03M 328.28M
EPS (Basic)
0.4811 0.5678 0.6146 0.233
EPS (Basic) Growth
+1.31% +18.02% +8.24% -62.09%
Basic Shares Outstanding
1.49B 1.46B 1.44B 1.41B
EPS (Diluted)
0.481 0.5677 0.6145 0.2327
EPS (Diluted) Growth
+1.28% +18.02% +8.24% -62.13%
Diluted Shares Outstanding
1.49B 1.47B 1.44B 1.41B
EBITDA
1.18B 1.25B 1.26B 592.18M
EBITDA Growth
+16.00% +6.12% +0.32% -52.87%
EBITDA Margin
+36.70% +37.96% +36.15% +18.54%

Snapshot

Average Recommendation UNDERWEIGHT Average Target Price 3.692
Number of Ratings 12 Current Quarters Estimate 0.018
FY Report Date 03 / 2026 Current Year's Estimate 0.308
Last Quarter’s Earnings 0.094 Median PE on CY Estimate N/A
Year Ago Earnings 0.245 Next Fiscal Year Estimate 0.331
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 N/A 10 10
Mean Estimate 0.02 N/A 0.31 0.33
High Estimates 0.05 N/A 0.33 0.37
Low Estimate -0.03 N/A 0.28 0.29
Coefficient of Variance 234.99 N/A 5.49 7.72

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 8 8 6
UNDERWEIGHT 1 1 1
SELL 3 3 3
MEAN Underweight Underweight Underweight

Ono Pharm in the News